Monitoring ADR Of Pemetrexed Platinum Chemotherapy in NSCLC
Not Applicable
Completed
- Conditions
- Health Condition 1: C00-D49- NeoplasmsHealth Condition 2: null- NSCLC patients and Mesothelioma patients
- Registration Number
- CTRI/2017/10/009960
- Lead Sponsor
- A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
1. Patients with histologically confirmed NSCLC or mesothelioma
2. Patients receiving first cycle of Pemtrexed + Platinum Doublet Chemotherapy
Exclusion Criteria
Patients having non-compliance to treatment schedule at Tata Memorial Centre
Patients not willing to give written informed consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence and severity of Adverse Drug ReactionsTimepoint: After the study completion
- Secondary Outcome Measures
Name Time Method Frequency of Grade 3/4 ADR <br/ ><br> <br/ ><br>Median Duration of Grade3/4 ADR <br/ ><br> <br/ ><br>Causality assessment using Naranjo scaleTimepoint: At the end of each cycle of chemotherapy